Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis
The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in ent...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/10/2387 |
| _version_ | 1827651462090457088 |
|---|---|
| author | Robert Gurke Annika Bendes John Bowes Michaela Koehm Richard M. Twyman Anne Barton Dirk Elewaut Carl Goodyear Lisa Hahnefeld Rainer Hillenbrand Ewan Hunter Mark Ibberson Vassilios Ioannidis Sabine Kugler Rik J. Lories Eduard Resch Stefan Rüping Klaus Scholich Jochen M. Schwenk James C. Waddington Phil Whitfield Gerd Geisslinger Oliver FitzGerald Frank Behrens Stephen R. Pennington |
| author_facet | Robert Gurke Annika Bendes John Bowes Michaela Koehm Richard M. Twyman Anne Barton Dirk Elewaut Carl Goodyear Lisa Hahnefeld Rainer Hillenbrand Ewan Hunter Mark Ibberson Vassilios Ioannidis Sabine Kugler Rik J. Lories Eduard Resch Stefan Rüping Klaus Scholich Jochen M. Schwenk James C. Waddington Phil Whitfield Gerd Geisslinger Oliver FitzGerald Frank Behrens Stephen R. Pennington |
| author_sort | Robert Gurke |
| collection | DOAJ |
| description | The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in entheseal and synovial musculoskeletal structures, but a definitive diagnosis often can only be made by clinical experts or when an extensive progressive disease state is apparent. As with other IMIDs, the detection of multimodal molecular biomarkers offers some hope for the early diagnosis of PsA and the initiation of effective management and treatment strategies. However, specific biomarkers are not yet available for PsA. The assessment of new markers by genomic and epigenomic profiling, or the analysis of blood and synovial fluid/tissue samples using proteomics, metabolomics and lipidomics, provides hope that complex molecular biomarker profiles could be developed to diagnose PsA. Importantly, the integration of these markers with high-throughput histology, imaging and standardized clinical assessment data provides an important opportunity to develop molecular profiles that could improve the diagnosis of PsA, predict its occurrence in cohorts of individuals with psoriasis, differentiate PsA from other IMIDs, and improve therapeutic responses. In this review, we consider the technologies that are currently deployed in the EU IMI2 project HIPPOCRATES to define biomarker profiles specific for PsA and discuss the advantages of combining multi-omics data to improve the outcome of PsA patients. |
| first_indexed | 2024-03-09T20:39:05Z |
| format | Article |
| id | doaj.art-8ed947e41a664f22a2b952f33211051f |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T20:39:05Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-8ed947e41a664f22a2b952f33211051f2023-11-23T23:02:13ZengMDPI AGBiomedicines2227-90592022-09-011010238710.3390/biomedicines10102387Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic ArthritisRobert Gurke0Annika Bendes1John Bowes2Michaela Koehm3Richard M. Twyman4Anne Barton5Dirk Elewaut6Carl Goodyear7Lisa Hahnefeld8Rainer Hillenbrand9Ewan Hunter10Mark Ibberson11Vassilios Ioannidis12Sabine Kugler13Rik J. Lories14Eduard Resch15Stefan Rüping16Klaus Scholich17Jochen M. Schwenk18James C. Waddington19Phil Whitfield20Gerd Geisslinger21Oliver FitzGerald22Frank Behrens23Stephen R. Pennington24Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyScience for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, 171 65 Solna, SwedenNIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WU, UKFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyTRM Ltd., P.O. Box 493, Scarborough YO11 9FJ, UKNIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WU, UKVIB-UGent Center for Inflammation Research, Ghent University, 9052 Ghent, BelgiumInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8QQ, UKFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyNovartis Pharma AG, CH-4056 Basel, SwitzerlandOxford BioDynamics Limited, Oxford OX4 2JZ, UKVital-IT Group, SIB Swiss Institute of Bioinformatics, CH-1015 Lausanne, SwitzerlandVital-IT Group, SIB Swiss Institute of Bioinformatics, CH-1015 Lausanne, SwitzerlandFraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyDepartment of Development and Regeneration, KU Leuven, Skeletal Biology and Engineering Research Centre, P.O. Box 813 O&N, Herestraat 49, 3000 Leuven, BelgiumFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyFraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyScience for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, 171 65 Solna, SwedenAtturos Ltd., c/o UCD Conway Institute, University College Dublin, D04 V1W8 Dublin, IrelandGlasgow Polyomics, College of Medical, Veterinary and Life Sciences, Garscube Campus, University of Glasgow, Glasgow G61 1QH, UKFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyUCD Conway Institute, School of Medicine, University College Dublin, Belfield, D04 V1W8 Dublin, IrelandFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, GermanyAtturos Ltd., c/o UCD Conway Institute, University College Dublin, D04 V1W8 Dublin, IrelandThe definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in ~30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in entheseal and synovial musculoskeletal structures, but a definitive diagnosis often can only be made by clinical experts or when an extensive progressive disease state is apparent. As with other IMIDs, the detection of multimodal molecular biomarkers offers some hope for the early diagnosis of PsA and the initiation of effective management and treatment strategies. However, specific biomarkers are not yet available for PsA. The assessment of new markers by genomic and epigenomic profiling, or the analysis of blood and synovial fluid/tissue samples using proteomics, metabolomics and lipidomics, provides hope that complex molecular biomarker profiles could be developed to diagnose PsA. Importantly, the integration of these markers with high-throughput histology, imaging and standardized clinical assessment data provides an important opportunity to develop molecular profiles that could improve the diagnosis of PsA, predict its occurrence in cohorts of individuals with psoriasis, differentiate PsA from other IMIDs, and improve therapeutic responses. In this review, we consider the technologies that are currently deployed in the EU IMI2 project HIPPOCRATES to define biomarker profiles specific for PsA and discuss the advantages of combining multi-omics data to improve the outcome of PsA patients.https://www.mdpi.com/2227-9059/10/10/2387psoriatic diseasespsoriatic arthritispsoriasismulti-omicsdata integration |
| spellingShingle | Robert Gurke Annika Bendes John Bowes Michaela Koehm Richard M. Twyman Anne Barton Dirk Elewaut Carl Goodyear Lisa Hahnefeld Rainer Hillenbrand Ewan Hunter Mark Ibberson Vassilios Ioannidis Sabine Kugler Rik J. Lories Eduard Resch Stefan Rüping Klaus Scholich Jochen M. Schwenk James C. Waddington Phil Whitfield Gerd Geisslinger Oliver FitzGerald Frank Behrens Stephen R. Pennington Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis Biomedicines psoriatic diseases psoriatic arthritis psoriasis multi-omics data integration |
| title | Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis |
| title_full | Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis |
| title_fullStr | Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis |
| title_full_unstemmed | Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis |
| title_short | Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis |
| title_sort | omics and multi omics analysis for the early identification and improved outcome of patients with psoriatic arthritis |
| topic | psoriatic diseases psoriatic arthritis psoriasis multi-omics data integration |
| url | https://www.mdpi.com/2227-9059/10/10/2387 |
| work_keys_str_mv | AT robertgurke omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT annikabendes omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT johnbowes omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT michaelakoehm omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT richardmtwyman omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT annebarton omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT dirkelewaut omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT carlgoodyear omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT lisahahnefeld omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT rainerhillenbrand omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT ewanhunter omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT markibberson omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT vassiliosioannidis omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT sabinekugler omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT rikjlories omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT eduardresch omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT stefanruping omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT klausscholich omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT jochenmschwenk omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT jamescwaddington omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT philwhitfield omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT gerdgeisslinger omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT oliverfitzgerald omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT frankbehrens omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis AT stephenrpennington omicsandmultiomicsanalysisfortheearlyidentificationandimprovedoutcomeofpatientswithpsoriaticarthritis |